The Embolic Protection Devices Market is projected to grow at a CAGR of 8.2% from 2024 to 2031. The market value is expected to increase from YY USD in 2024 to YY USD by 2031. North America currently dominates the market, with the highest market share and revenue. Key metrics include increasing prevalence of cardiovascular diseases, growing adoption of minimally invasive procedures, and technological advancements in embolic protection devices.
The market is experiencing significant growth due to the rising incidence of cardiovascular and neurovascular diseases globally. Embolic protection devices play a crucial role in preventing complications during endovascular procedures, driving their adoption in healthcare settings. The increasing geriatric population and the growing demand for effective treatment options for vascular diseases are also contributing to market expansion.
Market Trend: Rising adoption of transcatheter aortic valve replacement (TAVR) procedures
The increasing adoption of transcatheter aortic valve replacement (TAVR) procedures is a significant trend driving the embolic protection devices market. TAVR has emerged as a minimally invasive alternative to traditional open-heart surgery for treating severe aortic stenosis, particularly in high-risk patients. As TAVR procedures continue to gain popularity, the demand for embolic protection devices has surged to mitigate the risk of periprocedural stroke and other embolic complications.
The growing acceptance of TAVR among both patients and healthcare providers has led to a substantial increase in procedure volumes worldwide. This trend is further supported by expanding indications for TAVR, including its use in lower-risk patients. The need for embolic protection during TAVR procedures has become increasingly recognised, with clinical evidence demonstrating the potential benefits of these devices in reducing the risk of cerebral embolism and improving overall patient outcomes.
Moreover, ongoing technological advancements in embolic protection devices specifically designed for TAVR procedures are enhancing their efficacy and ease of use. These innovations are contributing to increased adoption rates and expanding the market for embolic protection devices in the context of structural heart interventions.
Market Driver: Increasing prevalence of cardiovascular and neurovascular diseases
The rising prevalence of cardiovascular and neurovascular diseases is a primary driver for the embolic protection devices market. Cardiovascular diseases, including coronary artery disease and peripheral artery disease, continue to be leading causes of morbidity and mortality worldwide. According to the World Health Organisation, cardiovascular diseases account for approximately 31% of all global deaths annually, with an estimated 17.9 million lives lost each year.
Similarly, the incidence of neurovascular diseases, such as stroke and cerebral aneurysms, is on the rise. Stroke remains a significant cause of disability and death globally, with ischaemic stroke accounting for about 87% of all stroke cases. The American Heart Association reports that someone in the United States has a stroke every 40 seconds, highlighting the magnitude of the problem.
This increasing disease burden has led to a growing number of endovascular procedures being performed to treat these conditions. Embolic protection devices are essential in minimising the risk of embolic complications during these interventions, driving their demand in clinical practice. The need for effective embolic protection is particularly critical in high-risk procedures such as carotid artery stenting, where the risk of periprocedural stroke is a significant concern.
Market Restraint: High costs associated with embolic protection devices
The high costs associated with embolic protection devices pose a significant restraint to market growth. The advanced technology and materials used in these devices contribute to their relatively high price points, which can limit their adoption, particularly in resource-constrained healthcare settings.
The cost of embolic protection devices can range from $1,000 to $2,500 per device, depending on the type and complexity. This expense is in addition to the overall procedural costs, which can be substantial for interventions such as carotid artery stenting or TAVR. The economic burden of these devices can impact healthcare providers' decisions to use them routinely, especially in cases where reimbursement is limited or uncertain.
Distal Filter Devices dominate the Embolic Protection Devices Market:
Distal filter devices currently hold the largest market share in the embolic protection devices segment. These devices are widely preferred due to their ability to capture and remove embolic debris while maintaining blood flow during endovascular procedures. The dominance of distal filter devices can be attributed to their versatility across various applications, including carotid artery stenting, saphenous vein graft interventions, and transcatheter aortic valve replacement (TAVR).
Recent advancements in distal filter technology have further solidified their market position. For instance, the introduction of next-generation filter designs with improved capture efficiency and lower crossing profiles has enhanced their performance and ease of use. A study published in the Journal of Vascular Surgery demonstrated that the use of distal filter devices during carotid artery stenting resulted in a 30% reduction in the incidence of periprocedural stroke compared to unprotected procedures.
Moreover, the expanding indications for distal filter devices have contributed to their market dominance. In addition to their established use in cardiovascular interventions, these devices are increasingly being employed in neurovascular procedures. The growing adoption of mechanical thrombectomy for acute ischaemic stroke treatment has created new opportunities for distal filter devices, as they can help prevent distal embolisation during clot retrieval.
Industry leaders have also played a crucial role in driving the adoption of distal filter devices. For example, Boston Scientific Corporation reported a 15% year-over-year increase in sales of its embolic protection portfolio, primarily attributed to the strong performance of its FilterWire EZ Embolic Protection System. Similarly, Medtronic plc has seen significant growth in its neurovascular business, partly due to the success of its Sentinel Cerebral Protection System, a distal filter device designed for use during TAVR procedures.
North America dominates the Embolic Protection Devices Market.
North America currently holds the largest market share in the global embolic protection devices market, with the United States being the primary contributor to this dominance. The region's leadership can be attributed to several factors, including the high prevalence of cardiovascular and neurovascular diseases, advanced healthcare infrastructure, and early adoption of innovative medical technologies.
The strong presence of key market players in North America has significantly contributed to market growth. Companies such as Abbott Laboratories, Boston Scientific Corporation, and Medtronic plc have their headquarters in the United States, facilitating rapid product launches and extensive marketing efforts in the region. These companies have also invested heavily in research and development, leading to the introduction of advanced embolic protection devices tailored to the needs of North American healthcare providers.
Recent market data indicates that the North American embolic protection devices market value exceeded $500 million in 2023, with a projected annual growth rate of 7.5% through 2031. This growth is primarily driven by the increasing number of endovascular procedures performed in the region, particularly in the areas of carotid artery stenting and structural heart interventions.
A key statistic supporting North America's market dominance is the high volume of carotid artery stenting procedures performed annually. According to the Society for Vascular Surgery, approximately 100,000 carotid interventions are performed each year in the United States with a growing proportion utilising embolic protection devices to minimise the risk of periprocedural stroke.
In terms of country-specific developments, Canada has also contributed significantly to the region's market leadership. The Canadian Agency for Drugs and Technologies in Health (CADTH) recently issued a positive recommendation for the use of embolic protection devices during TAVR procedures, which is expected to drive further adoption in the country. This decision was based on clinical evidence demonstrating a reduction in the risk of stroke and cognitive decline associated with the use of these devices during TAVR.
The embolic protection devices market is characterised by intense competition among key players, with a focus on technological innovation, strategic partnerships, and geographical expansion. Market leaders such as Abbott Laboratories, Boston Scientific Corporation, and Medtronic plc collectively hold a significant market share, leveraging their strong R&D capabilities and extensive distribution networks.
Abbott Laboratories has maintained its position as a market leader through its comprehensive portfolio of embolic protection devices, including the Emboshield NAV6 Embolic Protection System. The company's recent financial reports indicate a 12% year-over-year growth in its vascular business, partly attributed to the strong performance of its embolic protection devices segment.
Boston Scientific Corporation has focused on expanding its market presence through strategic acquisitions and product launches. The company's acquisition of Claret Medical in 2018 for $270 million strengthened its position in the TAVR embolic protection market. Boston Scientific reported a 15% increase in sales of its interventional cardiology devices, including embolic protection systems, in the latest fiscal year.
Medtronic plc has emphasised innovation in its embolic protection device portfolio, with a particular focus on neurovascular applications. The company's Solitaire X revascularisation device, used in conjunction with its embolic protection systems, has shown strong market performance. Medtronic's neurovascular business grew by 8% in the most recent quarter, driven by increased adoption of its thrombectomy and embolic protection technologies.
Emerging players such as Keystone Heart Ltd. (a Venus Medtech company) and Innovative Cardiovascular Solutions, LLC are gaining traction in the market with novel device designs. These companies are focused on addressing unmet needs in specific procedural applications, such as TAVR-specific embolic protection.
The competitive landscape is expected to evolve further with the entry of new players and ongoing clinical trials evaluating the efficacy of next-generation embolic protection devices. Market share dynamics may shift as healthcare providers increasingly prioritise evidence-based selection of embolic protection systems for various endovascular procedures.
The embolic protection devices market is poised for substantial growth in the coming years, driven by the increasing prevalence of cardiovascular and neurovascular diseases, coupled with the growing adoption of minimally invasive endovascular procedures. The market's expansion is further supported by technological advancements that are enhancing the efficacy and safety profiles of these devices.
An exclusive trend to watch is the development of procedure-specific embolic protection devices, particularly for emerging applications such as transcatheter mitral valve repair and replacement. This customisation approach is likely to open new avenues for market growth and provide opportunities for both established players and innovative start-ups.
Abbott Laboratories
Boston Scientific Corporation
Medtronic plc
Cardinal Health, Inc.
Silk Road Medical, Inc.
W. L. Gore & Associates, Inc.
Allium Medical Solutions Ltd.
Edwards Lifesciences Corporation
Keystone Heart Ltd. (Venus Medtech)
Innovative Cardiovascular Solutions, LLC
June 2023: Boston Scientific Corporation received FDA approval for its EMBOLD Fibred Detachable Coil System, expanding its embolic protection portfolio for neurovascular applications.
March 2023: Medtronic plc launched its next-generation Sentinel Cerebral Protection System in Europe, featuring enhanced deliverability and improved debris capture efficiency for TAVR procedures.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scandpe & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Abbott Laboratories
5.2. Boston Scientific Corporation
5.3. Medtronic plc
5.4. Cardinal Health, Inc.
5.5. Silk Road Medical, Inc.
5.6. W. L. Gore & Associates, Inc.
5.7. Allium Medical Solutions Ltd.
5.8. Edwards Lifesciences Corporation
5.9. Keystone Heart Ltd. (Venus Medtech)
5.10. Innovative Cardiovascular Solutions, LLC (LIST, NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Rising adoption of transcatheter aortic valve replacement (TAVR) procedures
6.1.2. Increasing focus on neurovascular embolic protection
6.1.3. Growing demand for multi-functional embolic protection devices
6.2. Market Drivers
6.2.1. Increasing prevalence of cardiovascular and neurovascular diseases
6.2.2. Technological advancements in embolic protection devices
6.2.3. Rising geriatric population and associated vascular complications
6.3. Market Restraints
6.3.1. High costs associated with embolic protection devices
6.3.2. Stringent regulatory approval processes
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY PRODUCT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Distal Filter Devices
7.1.1. Mesh-based filters
7.1.2. Micropore filters
7.2. Proximal Occlusion Devices
7.2.1. Balloon occlusion devices
7.2.2. Catheter-based occlusion devices
7.3. Distal Occlusion Devices
7.3.1. Balloon occlusion devices
7.3.2. Catheter-based occlusion devices
8. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2020-2031)
8.1. Cardiovascular Diseases
8.1.1. Coronary artery diseases
8.1.2. Structural heart diseases
8.2. Neurovascular Diseases
8.2.1. Stroke
8.2.2. Cerebral aneurysms
8.3. Peripheral Vascular Diseases
8.3.1. Peripheral artery disease
8.3.2. Deep vein thrombosis
9. BY MATERIAL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Nitinol
9.2. Polyurethane
9.3. Others
10. BY END-USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Hospitals
10.2. Ambulatory Surgical Centres
10.3. Cardiac Catheterisation Laboratories
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%, YOY GROWTH)--2020-2031.
By Product Type:
Distal Filter Devices
Proximal Occlusion Devices
Distal Occlusion Devices
By Application:
Cardiovascular Diseases
Neurovascular Diseases
Peripheral Vascular Diseases
By Material:
Nitinol
Polyurethane
By End-User:
Hospitals
Ambulatory Surgical Centres
Cardiac catheterisation laboratories
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
